Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have received an average rating of “Buy” from the nine analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $19.33.

ADAP has been the subject of several recent analyst reports. BidaskClub raised Adaptimmune Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 24th. Guggenheim assumed coverage on Adaptimmune Therapeutics in a report on Monday, September 17th. They set a “buy” rating for the company. TheStreet lowered Adaptimmune Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, July 16th. Zacks Investment Research lowered Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Finally, Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a report on Wednesday, August 15th.

Shares of Adaptimmune Therapeutics stock traded down $0.60 during midday trading on Wednesday, hitting $11.25. The company’s stock had a trading volume of 38,029 shares, compared to its average volume of 494,896. The stock has a market cap of $1.28 billion, a PE ratio of -14.19 and a beta of 1.06. Adaptimmune Therapeutics has a 1-year low of $6.60 and a 1-year high of $14.63.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.20). The business had revenue of $9.04 million during the quarter, compared to analyst estimates of $7.76 million. Adaptimmune Therapeutics had a negative return on equity of 47.22% and a negative net margin of 191.14%. As a group, research analysts anticipate that Adaptimmune Therapeutics will post -1.02 earnings per share for the current fiscal year.

In other Adaptimmune Therapeutics news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, August 29th. The stock was sold at an average price of $10.25, for a total transaction of $256,250.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ali Behbahani bought 12,000,000 shares of the business’s stock in a transaction on Friday, September 7th. The shares were bought at an average price of $1.67 per share, for a total transaction of $20,040,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ADAP. BlackRock Inc. raised its holdings in Adaptimmune Therapeutics by 2.5% during the first quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock valued at $9,062,000 after buying an additional 19,765 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Adaptimmune Therapeutics by 786.0% in the first quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock worth $2,085,000 after purchasing an additional 164,704 shares during the period. A.R.T. Advisors LLC bought a new position in shares of Adaptimmune Therapeutics in the first quarter worth about $953,000. Jane Street Group LLC bought a new position in shares of Adaptimmune Therapeutics in the first quarter worth about $168,000. Finally, Millennium Management LLC increased its stake in shares of Adaptimmune Therapeutics by 83.4% in the first quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock worth $16,594,000 after purchasing an additional 672,046 shares during the period. Institutional investors own 59.32% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Featured Article: Why investors pay attention to retained earnings

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.